Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. is a South San Francisco-based biopharmaceutical company focused on discovering, developing, and providing novel therapies that enhance the lives of people with immune and hematological disorders, cancers, and rare diseases. Rigel’s clinical development programs span multiple disease targets including chronic immune thrombocytopenia, autoimmune hemolytic anemia and IgA nephropathy.
The company's first FDA approved product TAVALISSE™ (fostamatinib disodium hexahydrate), was approved in April 2018. Please visit www.TAVALISSE.com to see the full Prescribing Information and to learn more.
Please visit Rigel at booth #1449 to learn more and support the ASH Foundation.